01PRP
RegenPRP™
Standardised leucocyte-reduced platelet concentrate.
RegenLab's core technology: autologous PRP prepared with a separator gel in a closed circuit with a single centrifugation. It is the basis of the other families.
01 · REGENLAB
RegenLab
Standardised PRP, designed in Switzerland.
Regen Lab SA is a Swiss medical device company, founded in 2003, that specialises in devices for cell-based therapies. Its core technology, RegenPRP™, produces a standardised, autologous platelet concentrate in a closed circuit. Evomedica supplies RegenLab products in Greece, with training and support for healthcare professionals.
TIMELINE · ACCORDING TO THE MANUFACTURER
- 2003Regen Lab SA founded (Switzerland)
- 2010First RegenKit approval in a bone graft application
- 2013New laboratory in Lausanne
- 2014First Cellular Matrix approval
- 2015Cellular Matrix launched in Europe
02 · WHAT IS REGENPRP™
A standardised platelet concentrate, from the patient's own blood.
RegenPRP™ is a standardised, leucocyte-reduced platelet concentrate. It is prepared in the clinic from a small volume of the patient's blood with a single centrifugation, for use in autologous regenerative medicine protocols.
PRP
Platelet-rich plasma
A concentrate of platelets in plasma, prepared from a sample of the patient's own blood.
PLATELETS
The role of platelets
Platelets contain growth factors such as PDGF, TGF-β, VEGF, EGF, FGF and IGF.
PLASMA
The role of plasma
According to RegenLab, the plasma is fully recovered. The fibrin it contains forms a natural scaffold.
AUTOLOGOUS
Autologous preparation
Closed circuit, small blood volume and pharmaceutical-grade sodium citrate as a reversible anticoagulant.
SEPARATION
Separation technology
A chemically inert separator gel and mechanical separation, with a single centrifugation at 1500 × g for about 5 minutes.
STANDARDISATION
Standardisation
Each device produces a leucocyte-reduced platelet concentrate with a consistent composition, according to the manufacturer.
SCHEMATIC · SEPARATION PRINCIPLE1500 × g · ~5′
Schematic illustration of the gel separation principle — it does not depict a product or tube; proportions are indicative. Centrifugation parameters as stated on the RegenPRP™ and Cellular Matrix Skin pages.
- 01Blood drawSmall blood volume, closed circuit.
- 02CentrifugationA single centrifugation · 1500 × g · ~5 minutes.
- 03SeparationThe gel separates the red blood cells.
- 04RegenPRP™Collection according to the instructions for use.
The procedure is performed by a healthcare professional according to the instructions for use (IFU) of each product.
03 · TECHNOLOGIES
One separation technology, four product families.
All families are built on the same gel separation technology. The products of each family are shown in section 04.
02PRP + HA
RegenPRP™-HA
RegenPRP™ combined with hyaluronic acid (Cellular Matrix).
Devices for preparing a combination of autologous RegenPRP™ and hyaluronic acid. The manufacturer presents two Cellular Matrix versions with different intended uses.
03PRP + ATS
RegenPRP™ + ATS
RegenPRP™ with autologous thrombin serum.
Autologous thrombin serum (ATS) is prepared with the RegenATS™ device and, according to the manufacturer, physiologically initiates the clotting process, producing a leucocyte-reduced platelet gel. A calcium solution may be added.
04BMC
RegenExtracell BMC®
Bone marrow concentrate system.
The manufacturer describes it as a versatile, reproducible bone marrow concentrate (BMC) system, with RegenBMC separator-gel tubes and single-step processing during the procedure.
04 · PRODUCTS
RegenLab products.
Devices for preparing PRP with hyaluronic acid, platelet gel and bone marrow concentrate.
RegenPRP™-HA · Cellular Matrix CM-OA
Device for preparing a combination of autologous RegenPRP™ and hyaluronic acid.
- Intended use (manufacturer)
- Intra-articular injections for symptomatic treatment of pain and improved mobility in knee osteoarthritis
View the product RegenPRP™-HA · Cellular Matrix CM-OA (opens in a new tab)Source: regenlab.com/regenprp-ha
RegenPRP™-HA · Cellular Matrix Skin
Device for preparing a combination of hyaluronic acid and autologous RegenPRP™ for dermal use.
- Intended use (manufacturer)
- Preparation of a combination of HA and autologous RegenPRP™ for dermal use
- Hyaluronic acid
- 2 ml non-cross-linked HA, 20 mg/ml (40 mg), from bacterial fermentation
- Centrifugation
- 5 minutes at 1500 × g
View the product RegenPRP™-HA · Cellular Matrix Skin (opens in a new tab)Source: regenlab.com/regenprp-ha-cellular-matrix-skin
RegenATS™
Device for preparing autologous thrombin serum (ATS), used with RegenPRP™ to form a platelet gel.
View the product RegenATS™ (opens in a new tab)Source: regenlab.com · RegenPRP + ATS
RegenExtracell BMC® · RegenBMC tubes
Bone marrow concentrate system with RegenBMC tubes containing separator gel, for single-step processing during the procedure.
View the product RegenExtracell BMC® · RegenBMC tubes (opens in a new tab)Source: regenlab.com/extracell-bmc
"View the product" opens the product page on regenlab.com.
05 · ADVANTAGES
Designed for standardisation and reproducibility.
The key features of the technology, as described by the manufacturer.
01Closed circuit
Preparation takes place in a closed system, from collection to PRP retrieval.
RegenPRP™ · manufacturer02Single centrifugation
One centrifugation step at 1500 × g for about 5 minutes.
RegenPRP™ · CM-Skin03Inert separator gel
Mechanical separation with a chemically inert gel.
RegenPRP™ · manufacturer04Leucocyte-reduced
A standardised, leucocyte-reduced platelet concentrate.
RegenPRP™ · manufacturer05Small blood volume
Only a small volume of blood is needed.
RegenPRP™ · manufacturer06Reversible anticoagulation
Pharmaceutical-grade sodium citrate.
RegenPRP™ · manufacturer07GMP manufacturing
GMP-compliant production with atmosphere monitoring for a non-pyrogenic product, according to the manufacturer.
Regen Lab SA · quality08Clinical support
The manufacturer's RegenClinic® marketing and clinical support programme, together with training from Evomedica in Greece.
RegenClinic® · manufacturer06 · SCIENTIFIC EVIDENCE
What the manufacturer says and what has been published.
We present the manufacturer's descriptions, published studies and the products' intended uses separately. Study topics are not approved indications.
A · MANUFACTURER STATEMENTS
Technology, quality and company information from regenlab.com.
B · PUBLISHED DATA
Study summaries as presented by the manufacturer.
- Knee osteoarthritis · PRP-HABarac 2018 · Renevier 2018
- Knee osteoarthritis · meta-analysis2025 · 43 clinical trials · standardised PRP
- Facial appearance · PRP-HAHersant 2021 · Aesthetic Surgery Journal
- Chronic wounds · PRP + ATSKontopodis · Rainys
- Achilles tendinopathySalini 2015
- Androgenetic alopeciaManufacturer summary
- Female sexual dysfunctionRunels 2014
- Stress urinary incontinenceLong 2021
- Bone marrow concentrateHolton 2016 · Frontiers in Surgery
Information exclusively for healthcare professionals. This information does not replace the instructions for use (IFU). Approved indications, contraindications and availability may vary by country.
07 · CONTACT
Interested in RegenLab products?
Choose a topic and the Evomedica team will contact you about information, orders or training. For healthcare professionals.